636 studies on GLP-1 agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This updated prevalence data highlights the growing acceptance and utilization of effective anti-obesity medications within a critical military population. Understanding these trends is vital for resource allocation, …
The impressive 24% body weight reduction observed with retatrutide represents a significant leap forward in obesity pharmacotherapy, potentially offering efficacy comparable to bariatric surgery for some individuals. …
This study provides compelling evidence that dual and triple incretin agonists offer superior glycemic control and weight loss benefits compared to current GLP-1 receptor agonists for patients with Type 2 Diabetes. Th…
This study highlights the potential of retatrutide to not only manage blood glucose but also to directly address the underlying appetite dysregulation in type 2 diabetes and obesity. By improving appetite control and …
The designed triagonist, xGLP/GCG/GIP-32, demonstrated a distinct pharmacological profile, characterized by strong agonism at the GLP-1R and GCGR, coupled with significantly less potent activation of the GIPR (glucose…
These advancements collectively represent a significant leap forward in nephrology, offering new hope for patients with various kidney conditions. The expansion of complement inhibitors and the efficacy of GLP-1 recep…
This perspective highlights that Retatrutide exemplifies rational multi-agonist peptide engineering, signaling a paradigm shift in systems pharmacology for obesity and related conditions. Its unprecedented efficacy su…
This review underscores the transformative potential of multi-target incretin-based therapeutics for metabolic disorders. These agents could significantly expand the therapeutic arsenal for patients struggling with ty…
Understanding the precise chemical structure and identity of compounds like semaglutide is absolutely critical for pharmaceutical development, ensuring drug purity, consistency, and regulatory compliance. This detaile…
This upcoming clinical trial holds significant promise for patients battling both Type 2 Diabetes and Coronary Arterial Disease, a population at high risk for severe cardiovascular events. If successful, the findings …
While the detailed quantitative results from this completed clinical trial are not yet publicly available in this record, the study successfully concluded its primary objective of assessing Tirzepatide's influence on …
The insights gained from this study are crucial for advancing personalized treatment strategies for individuals with co-occurring obesity and Binge Eating Disorder. By understanding how GLP-1 analogues interact with b…
The findings from this Phase 1 study are critically important for the future development of LY3437943. Understanding the impact of hepatic impairment on drug pharmacokinetics is essential for establishing safe and eff…
This review critically underscores a significant public health need for more robust research into the safety and efficacy of GLP-1 receptor agonists in reproductive-aged women. Given the global rise in obesity and the…
This review highlights a rapidly evolving therapeutic landscape for MASLD in T2D, moving towards integrated metabolic, hepatic, and cardiovascular risk reduction. The identification of agents like semaglutide and resm…